Morgan Stanley Upgrades Quest Diagnostics (DGX) to Overweight; to Benefit from Shifts to Phase II of COVID-19 Testing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. NVDA
3. GNK
4. PLUR
5. AZN
6. SPCX
7. FNGR
8. GSAT
9. S
10. AGPU

Go back to Morgan Stanley Upgrades Quest Diagnostics (DGX) to Overweight; to Benefit from Shifts to Phase II of COVID-19 Testing
Quest Diagnostics (NYSE: DGX) Delayed: 236.54 +2.14 (0.91%)
Previous Close $234.40    52 Week High $86.85 
Open $233.94    52 Week Low $59.66 
Day High $236.75    P/E 44.55 
Day Low $233.00    EPS $5.31 
Volume 92,697